Heart Failure in Ischemic Stroke: Relevance for Acute Care and Outcome.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
11 2019
Historique:
pubmed: 29 9 2019
medline: 31 3 2020
entrez: 28 9 2019
Statut: ppublish

Résumé

Background and Purpose- Heart failure (HF) in patients with acute ischemic stroke constitutes the source of various detrimental pathophysiologic mechanisms including prothrombotic and proinflammatory states, worsening of cerebral tissue oxygenation, and hemodynamic impairment. In addition, HF might affect the safety and efficacy of the acute recanalization stroke therapies. Methods- Patients treated with intravenous recombinant tissue-type plasminogen activator or mechanical recanalization at a universitary stroke center were included into a prospective registry. Patients received cardiological evaluation, including echocardiography, during acute care. Functional outcome was assessed after 90 days by structured telephone interviews. Safety and efficacy of intravenous thrombolysis and mechanical thrombectomy were investigated among patients with HF and compared with patients with normal cardiac function after propensity score matching. Results- One thousand two hundred nine patients were included. HF was present in 378 patients (31%) and an independent predictor of unfavorable functional outcome. Recanalization rates were equal among patients with HF after intravenous thrombolysis and after mechanical recanalization or combined treatment. The rate of secondary intracranial hemorrhage was not different (7% versus 8%;

Identifiants

pubmed: 31558143
doi: 10.1161/STROKEAHA.119.026139
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Clinical Trial Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3051-3056

Auteurs

Gabriela Siedler (G)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Kim Sommer (K)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Kosmas Macha (K)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Armin Marsch (A)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Lorenz Breuer (L)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Svenja Stoll (S)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Tobias Engelhorn (T)

Department of Neuroradiology (T.E., A.D.), University Hospital Erlangen, Germany.

Arnd Dörfler (A)

Department of Neuroradiology (T.E., A.D.), University Hospital Erlangen, Germany.

Martin Arnold (M)

Department of Cardiology (M.A.), University Hospital Erlangen, Germany.

Stefan Schwab (S)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Bernd Kallmünzer (B)

From the Department of Neurology (G.S., K.S., K.M., A.M., L.B., S. Stoll, S. Schwab, B.K.), University Hospital Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH